EGFR and lung cancer: Crucial targets of Hsp90-active drugs vary in different cell types, and Hsp90 is permissive for the development of mutant EGFR-dependent lung cancers, these kinase domain mutants are degraded by Hsp90 inhibitors [20, 33].